drugset / Trial / NCT04123405
Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis
RandomizedParallel-groupDouble-blindTreatment
Summary
The trial was conducted as a prospective, randomized, multinational, multicenter, double-blind study in 4 parallel groups of patients.
Timeline
- Start
- 2020-10-22
- Primary completion
- 2021-04-20
- Completion
- 2021-04-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-acetylcysteine | Small molecule | 600 mg | Oral |
| Subject | N-acetylcysteine | Small molecule | 1200 mg | Oral |
| Subject | N-acetylcysteine | Small molecule | 2400 mg | Oral |